Literature DB >> 29959531

Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?

Shuichiro Fujinaga1, Koji Sakuraya2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29959531     DOI： 10.1007/s00467-018-3993-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  2 in total

1.  A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Yoshiyuki Ohtomo; Daisuke Umino; Mayako Takemoto; Toshiaki Shimizu; Yuichiro Yamashiro; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2006-11-04       Impact factor: 3.714

2.  Mycophenolate mofetil for sustained remission in nephrotic syndrome.

Authors:  Uwe Querfeld; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2018-05-11       Impact factor: 3.714
  2 in total
  2 in total

1.  Treatment strategies for children with steroid-dependent nephrotic syndrome: in need of controlled studies.

Authors:  Uwe Querfeld; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2018-07-02       Impact factor: 3.714

2.  Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Tomohiko Nishino; Chisato Umeda; Yoshitaka Watanabe; Mayu Nakagawa
Journal:  Pediatr Nephrol       Date:  2019-08-21       Impact factor: 3.714
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.